Hybio Pharmaceutical Co., Ltd. (300199.SZ)
CNY 13.0
(4.17%)
CNY 13.0
(4.17%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 172.85 Million CNY | -60.95% |
| 2022 | 544.69 Million CNY | 2.73% |
| 2021 | 530.2 Million CNY | -8.72% |
| 2020 | 580.83 Million CNY | 18.91% |
| 2019 | 488.46 Million CNY | -54.85% |
| 2018 | 1.08 Billion CNY | 3.09% |
| 2017 | 1.04 Billion CNY | 53.07% |
| 2016 | 685.61 Million CNY | 10.31% |
| 2015 | 621.51 Million CNY | 78.87% |
| 2014 | 347.46 Million CNY | 36.16% |
| 2013 | 255.19 Million CNY | 42.35% |
| 2012 | 179.27 Million CNY | 41.05% |
| 2011 | 127.09 Million CNY | 37.45% |
| 2010 | 92.46 Million CNY | 27.79% |
| 2009 | 72.36 Million CNY | 37.59% |
| 2008 | 52.59 Million CNY | 67.46% |
| 2007 | 31.4 Million CNY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 89.4 Million CNY | 312.0% |
| 2024 Q2 | 41.94 Million CNY | -53.09% |
| 2024 Q3 | 69.86 Million CNY | 66.58% |
| 2023 Q3 | 23.01 Million CNY | -78.13% |
| 2023 FY | 212.69 Million CNY | -60.95% |
| 2023 Q2 | 105.22 Million CNY | -16.9% |
| 2023 Q4 | -42.17 Million CNY | -283.28% |
| 2023 Q1 | 126.63 Million CNY | -0.82% |
| 2022 Q1 | 129.47 Million CNY | -20.81% |
| 2022 Q4 | 127.67 Million CNY | -9.54% |
| 2022 Q3 | 141.14 Million CNY | -3.58% |
| 2022 FY | 544.69 Million CNY | 2.73% |
| 2022 Q2 | 146.39 Million CNY | 13.06% |
| 2021 Q3 | 100.25 Million CNY | -26.91% |
| 2021 Q1 | 129.27 Million CNY | 1013.28% |
| 2021 Q2 | 137.17 Million CNY | 6.11% |
| 2021 Q4 | 163.49 Million CNY | 63.08% |
| 2021 FY | 530.2 Million CNY | -8.72% |
| 2020 FY | 580.83 Million CNY | 18.91% |
| 2020 Q4 | 11.61 Million CNY | -94.62% |
| 2020 Q3 | 215.94 Million CNY | 7.2% |
| 2020 Q2 | 201.43 Million CNY | 32.66% |
| 2020 Q1 | 151.84 Million CNY | 307.92% |
| 2019 Q4 | 37.22 Million CNY | -49.4% |
| 2019 FY | 488.46 Million CNY | -54.85% |
| 2019 Q1 | 167.58 Million CNY | -44.58% |
| 2019 Q2 | 210.09 Million CNY | 25.36% |
| 2019 Q3 | 73.56 Million CNY | -64.99% |
| 2018 Q2 | 331.48 Million CNY | 41.76% |
| 2018 Q1 | 233.83 Million CNY | -50.17% |
| 2018 FY | 1.08 Billion CNY | 3.09% |
| 2018 Q4 | 302.42 Million CNY | 41.2% |
| 2018 Q3 | 214.18 Million CNY | -35.39% |
| 2017 Q3 | 194.9 Million CNY | -14.41% |
| 2017 FY | 1.04 Billion CNY | 53.07% |
| 2017 Q2 | 227.72 Million CNY | 44.57% |
| 2017 Q1 | 157.51 Million CNY | -15.27% |
| 2017 Q4 | 469.29 Million CNY | 140.78% |
| 2016 Q3 | 226.52 Million CNY | 57.2% |
| 2016 FY | 685.61 Million CNY | 10.31% |
| 2016 Q2 | 144.09 Million CNY | 11.63% |
| 2016 Q1 | 129.08 Million CNY | -49.56% |
| 2016 Q4 | 185.91 Million CNY | -17.93% |
| 2015 Q3 | 157.74 Million CNY | 37.16% |
| 2015 Q4 | 255.91 Million CNY | 62.23% |
| 2015 Q1 | 92.84 Million CNY | -16.38% |
| 2015 Q2 | 115 Million CNY | 23.86% |
| 2015 FY | 621.51 Million CNY | 78.87% |
| 2014 Q3 | 104.32 Million CNY | 42.43% |
| 2014 Q4 | 111.03 Million CNY | 6.44% |
| 2014 Q2 | 73.24 Million CNY | 24.43% |
| 2014 Q1 | 58.86 Million CNY | -42.77% |
| 2014 FY | 347.46 Million CNY | 36.16% |
| 2013 Q3 | 57.84 Million CNY | 1.36% |
| 2013 Q1 | 37.43 Million CNY | -37.43% |
| 2013 Q2 | 57.06 Million CNY | 52.42% |
| 2013 Q4 | 102.84 Million CNY | 77.81% |
| 2013 FY | 255.19 Million CNY | 42.35% |
| 2012 Q4 | 59.83 Million CNY | 36.73% |
| 2012 Q1 | 30.88 Million CNY | -26.44% |
| 2012 FY | 179.27 Million CNY | 41.05% |
| 2012 Q2 | 44.79 Million CNY | 45.05% |
| 2012 Q3 | 43.75 Million CNY | -2.32% |
| 2011 Q1 | 25.33 Million CNY | -22.3% |
| 2011 Q2 | 29.01 Million CNY | 14.52% |
| 2011 Q3 | 30.76 Million CNY | 6.02% |
| 2011 Q4 | 41.98 Million CNY | 36.5% |
| 2011 FY | 127.09 Million CNY | 37.45% |
| 2010 FY | 92.46 Million CNY | 27.79% |
| 2010 Q1 | 10.59 Million CNY | 0.0% |
| 2010 Q3 | 21.53 Million CNY | -22.38% |
| 2010 Q2 | 27.73 Million CNY | 161.9% |
| 2010 Q4 | 32.6 Million CNY | 51.45% |
| 2009 FY | 72.36 Million CNY | 37.59% |
| 2008 FY | 52.59 Million CNY | 67.46% |
| 2007 FY | 31.4 Million CNY | 0.0% |